Tamoxifen has been approved by the FDA for adjuvant hormone treatment of premenopausal or postmenopausal women as well as men with ER-positive early-stage breast cancer, and anastrozole, letrozole, ...

Breast cancer is the most common cancer among women worldwide (WHO, 2023). The Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) has now developed a new therapy in a clinical study ...

Treatment cuts risk of death and recurrence, but some women still go without. July 29, 2011— -- For women diagnosed with hormone-sensitive breast cancer-- more than 150,000 in the U.S. each year- ...

Breast cancer is the most common cancer among women worldwide (WHO, 2023). The Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) has now developed a new therapy in a clinical study ...

The hormone therapy tamoxifen can keep cancer from recurring in women with DCIS Tamoxifen following lumpectomy reduced risk of recurrence 44% to 51% Tamoxifen blocks estrogen receptors in cancer cells ...

Oct 17 (Reuters) - Researchers appear to have found a solution for breast cancer patients who do not respond well enough to the common treatment tamoxifen, according to results from a German study.

Emerging from the battle with breast cancer is a triumph like no other. You’ve faced the fear, endured the treatments, and emerged victorious. But for many survivors, the journey doesn’t end with ...

In a preclinical study, researchers found tamoxifen encourages uterine cell growth; the findings could change how some breast cancers are treated in the future Studies show that people receiving ...

- ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the HER2 ...

The Breast International Group (BIG) 1-98 study evaluated adjuvant endocrine therapy in postmenopausal women who had hormone receptor-positive early-stage breast cancer. The study participants were ...